What is Inspiremd's earnings per share (EPS)?

Inspiremd (NSPR) reported diluted earnings per share of $-0.76 for fiscal year 2024. This represents a 7.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Inspiremd Financials

NSPR

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Inspiremd (NSPR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 42/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Inspiremd has an operating margin of -478.0%, meaning the company retains $-478 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -340.7% the prior year.

Growth

Inspiremd's revenue grew 13.0% year-over-year to $7.0M, a solid pace of expansion. This earns a growth score of 55/100.

Leverage

Inspiremd carries a low D/E ratio of 0.30, meaning only $0.30 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 5.28, Inspiremd holds $5.28 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Inspiremd generated -$21.9M in operating cash flow, capex of $1.4M consumed most of it, leaving -$23.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Inspiremd generates a -88.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -50.4% the prior year.

Piotroski F-Score Weak

2/9

Inspiremd passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.68x

For every $1 of reported earnings, Inspiremd generates $0.68 in operating cash flow (-$21.9M OCF vs -$32.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$7.0M

YoY+13.0%

5Y CAGR+13.5%

10Y CAGR+9.5%

Inspiremd generated $7.0M in revenue in fiscal year 2024. This represents an increase of 13.0% from the prior year.

EBITDA

$246.5M

YoY+16.9%

Inspiremd's EBITDA was $246.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.9% from the prior year.

Net Income

-$32.0M

YoY-60.7%

Inspiremd reported -$32.0M in net income in fiscal year 2024. This represents a decrease of 60.7% from the prior year.

EPS (Diluted)

$-0.76

YoY+7.3%

Inspiremd earned $-0.76 per diluted share (EPS) in fiscal year 2024. This represents an increase of 7.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$23.3M

YoY-38.9%

Inspiremd generated -$23.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 38.9% from the prior year.

Cash & Debt

$18.9M

YoY+96.2%

5Y CAGR+28.0%

10Y CAGR+11.6%

Inspiremd held $18.9M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

27M

YoY+21.8%

5Y CAGR+46.7%

Inspiremd had 27M shares outstanding in fiscal year 2024. This represents an increase of 21.8% from the prior year.

Margins & Returns

Gross Margin

21.5%

YoY-7.6pp

5Y CAGR+1.2pp

10Y CAGR-6.3pp

Inspiremd's gross margin was 21.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 7.6 percentage points from the prior year.

Operating Margin

-478.0%

YoY-137.3pp

5Y CAGR-214.2pp

10Y CAGR+362.9pp

Inspiremd's operating margin was -478.0% in fiscal year 2024, reflecting core business profitability. This is down 137.3 percentage points from the prior year.

Net Margin

-456.6%

YoY-135.7pp

5Y CAGR-186.8pp

10Y CAGR+433.9pp

Inspiremd's net profit margin was -456.6% in fiscal year 2024, showing the share of revenue converted to profit. This is down 135.7 percentage points from the prior year.

Return on Equity

-88.7%

YoY-38.3pp

5Y CAGR+97.8pp

Inspiremd's ROE was -88.7% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 38.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$13.6M

YoY+70.8%

5Y CAGR+35.8%

10Y CAGR+4.5%

Inspiremd invested $13.6M in research and development in fiscal year 2024. This represents an increase of 70.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.4M

YoY+268.0%

5Y CAGR+37.6%

10Y CAGR+26.6%

Inspiremd invested $1.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 268.0% from the prior year.

NSPR Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$7.0M+13.0%	$6.2M+20.0%	$5.2M+15.0%	$4.5M+80.9%	$2.5M-33.2%	$3.7M
Cost of Revenue	$5.5M+25.1%	$4.4M+8.5%	$4.1M+8.4%	$3.7M+55.7%	$2.4M-19.0%	$3.0M
Gross Profit	$1.5M-16.7%	$1.8M+61.8%	$1.1M+48.1%	$754K+808.4%	$83K-89.0%	$756K
R&D Expenses	$13.6M+70.8%	$8.0M+2.2%	$7.8M+51.4%	$5.2M+131.0%	$2.2M-24.4%	$3.0M
SG&A Expenses	$15.3M+37.8%	$11.1M+32.9%	$8.4M+12.8%	$7.4M+20.9%	$6.1M+17.3%	$5.2M
Operating Income	-$33.5M-58.5%	-$21.1M-13.0%	-$18.7M-27.2%	-$14.7M-41.8%	-$10.4M-5.7%	-$9.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$59K-9.2%	$65K+132.1%	$28K-37.8%	$45K+1025.0%	$4K-83.3%	$24K
Net Income	-$32.0M-60.7%	-$19.9M-7.7%	-$18.5M-24.0%	-$14.9M-41.5%	-$10.5M-5.0%	-$10.0M
EPS (Diluted)	$-0.76+7.3%	$-0.82+65.1%	$-2.35	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$2.5M+41.9%	$1.8M+16.3%	$1.5M-21.5%	$1.9M+7.7%	$1.8M+4.1%	$1.7M+15.1%	$1.5M-14.2%	$1.8M
Cost of Revenue	$1.7M+13.2%	$1.5M+18.4%	$1.2M-16.4%	$1.5M+6.0%	$1.4M-0.9%	$1.4M+15.5%	$1.2M-2.9%	$1.3M
Gross Profit	$864K+176.0%	$313K+7.2%	$292K-37.7%	$469K+13.3%	$414K+25.1%	$331K+13.4%	$292K-42.2%	$505K
R&D Expenses	$3.6M-5.2%	$3.8M-5.5%	$4.1M+9.9%	$3.7M-5.7%	$3.9M+15.1%	$3.4M+29.6%	$2.6M+29.0%	$2.0M
SG&A Expenses	$5.9M+10.6%	$5.3M+7.7%	$4.9M+16.9%	$4.2M+21.2%	$3.5M-6.8%	$3.7M-2.6%	$3.8M+29.5%	$3.0M
Operating Income	-$13.1M-0.2%	-$13.0M-13.6%	-$11.5M-22.3%	-$9.4M-10.7%	-$8.5M-2.4%	-$8.3M-11.4%	-$7.4M-27.7%	-$5.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$12.7M+3.4%	-$13.2M-17.8%	-$11.2M-21.7%	-$9.2M-16.3%	-$7.9M+0.2%	-$7.9M-12.5%	-$7.0M-30.1%	-$5.4M
EPS (Diluted)	$-0.17+34.6%	$-0.26-18.2%	$-0.22	N/A	$-0.16+27.3%	$-0.22-4.8%	$-0.21	N/A

NSPR Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$46.8M-1.8%	$47.6M+93.3%	$24.7M-37.9%	$39.7M+123.4%	$17.8M+79.9%	$9.9M
Current Assets	$40.5M-8.2%	$44.2M+107.1%	$21.3M-42.5%	$37.1M+141.8%	$15.3M+96.4%	$7.8M
Cash & Equivalents	$18.9M+96.2%	$9.6M+108.1%	$4.6M-61.4%	$12.0M-5.1%	$12.6M+129.3%	$5.5M
Inventory	$2.6M+22.0%	$2.1M+29.9%	$1.6M+41.8%	$1.1M-19.2%	$1.4M+14.5%	$1.2M
Accounts Receivable	$1.6M-12.9%	$1.8M+74.5%	$1.0M-15.5%	$1.2M+157.1%	$476K-42.2%	$823K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.7M+31.7%	$8.1M+12.1%	$7.3M+17.5%	$6.2M+10.1%	$5.6M+24.8%	$4.5M
Current Liabilities	$7.7M+27.5%	$6.0M+18.7%	$5.1M+16.6%	$4.3M+17.3%	$3.7M+18.9%	$3.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$36.1M-8.6%	$39.5M+127.1%	$17.4M-48.1%	$33.5M+175.7%	$12.2M+126.0%	$5.4M
Retained Earnings	-$253.5M-14.4%	-$221.5M-9.9%	-$201.6M-10.1%	-$183.1M-8.9%	-$168.2M-6.7%	-$157.6M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$78.5M+135.4%	$33.3M-13.8%	$38.7M-17.4%	$46.8M-7.3%	$50.5M-9.3%	$55.7M+32.4%	$42.0M-11.8%	$47.6M
Current Assets	$70.4M+176.4%	$25.5M-20.8%	$32.1M-20.7%	$40.5M-12.7%	$46.4M-10.5%	$51.8M+34.6%	$38.5M-12.8%	$44.2M
Cash & Equivalents	$63.4M+450.9%	$11.5M-7.1%	$12.4M-34.5%	$18.9M+19.6%	$15.8M-44.3%	$28.4M+202.3%	$9.4M-2.6%	$9.6M
Inventory	$3.6M+18.1%	$3.1M+8.2%	$2.8M+9.8%	$2.6M+5.1%	$2.4M+10.8%	$2.2M-6.5%	$2.4M+12.1%	$2.1M
Accounts Receivable	$2.0M+23.2%	$1.6M+0.8%	$1.6M+0.5%	$1.6M+2.7%	$1.5M+17.1%	$1.3M+10.1%	$1.2M-34.2%	$1.8M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$14.4M+9.6%	$13.1M+26.8%	$10.3M-3.7%	$10.7M+17.4%	$9.1M+2.6%	$8.9M+28.2%	$6.9M-14.8%	$8.1M
Current Liabilities	$10.8M+19.3%	$9.1M+23.1%	$7.4M-4.1%	$7.7M+5.7%	$7.3M+4.3%	$7.0M+42.8%	$4.9M-19.0%	$6.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$64.1M+216.7%	$20.2M-28.6%	$28.3M-21.5%	$36.1M-12.7%	$41.4M-11.6%	$46.8M+33.3%	$35.1M-11.2%	$39.5M
Retained Earnings	-$290.5M-4.6%	-$277.8M-5.0%	-$264.7M-4.4%	-$253.5M-3.8%	-$244.3M-3.3%	-$236.4M-3.5%	-$228.5M-3.2%	-$221.5M

NSPR Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$21.9M-33.5%	-$16.4M-5.4%	-$15.5M-17.7%	-$13.2M-45.5%	-$9.1M+7.4%	-$9.8M
Capital Expenditures	$1.4M+268.0%	$381K-19.5%	$473K+37.5%	$344K+290.9%	$88K-69.0%	$284K
Free Cash Flow	-$23.3M-38.9%	-$16.8M-4.6%	-$16.0M-18.2%	-$13.6M-47.8%	-$9.2M+9.2%	-$10.1M
Investing Cash Flow	$12.6M+178.6%	-$16.1M-290.6%	$8.4M+137.6%	-$22.5M-11909.1%	-$187K+51.7%	-$387K
Financing Cash Flow	$18.5M-50.8%	$37.5M+26910.0%	-$140K-100.4%	$35.0M+113.7%	$16.4M+158.8%	$6.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$8.6M-3.6%	-$8.3M+5.2%	-$8.8M-30.3%	-$6.8M-18.4%	-$5.7M-30.9%	-$4.4M+14.0%	-$5.1M-21.2%	-$4.2M
Capital Expenditures	$329K-42.9%	$576K+60.4%	$359K+15.4%	$311K-26.1%	$421K-11.4%	$475K+143.6%	$195K-9.3%	$215K
Free Cash Flow	-$9.0M-0.6%	-$8.9M+2.6%	-$9.2M-29.6%	-$7.1M-15.4%	-$6.1M-26.8%	-$4.8M+8.2%	-$5.3M-19.7%	-$4.4M
Investing Cash Flow	$7.6M+41.9%	$5.3M+212.7%	$1.7M-79.3%	$8.2M+239.1%	-$5.9M-207.6%	$5.5M+14.3%	$4.8M+13480.6%	-$36K
Financing Cash Flow	$52.9M+2376.6%	$2.1M+322.3%	$506K-67.6%	$1.6M+262.0%	-$965K	N/A	N/A	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NSPR Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	21.5%-7.6pp	29.1%+7.5pp	21.6%+4.8pp	16.8%+13.4pp	3.3%-17.0pp	20.3%
Operating Margin	-478.0%-137.3pp	-340.7%+21.1pp	-361.9%-34.5pp	-327.4%+90.3pp	-417.7%-153.9pp	-263.8%
Net Margin	-456.6%-135.7pp	-321.0%+36.6pp	-357.6%-25.7pp	-331.9%+92.4pp	-424.3%-154.5pp	-269.8%
Return on Equity	-88.7%-38.3pp	-50.4%+55.9pp	-106.3%-61.8pp	-44.5%+42.2pp	-86.7%+99.8pp	-186.5%
Return on Assets	-68.4%-26.6pp	-41.8%+33.2pp	-75.0%-37.4pp	-37.6%+21.7pp	-59.3%+42.3pp	-101.6%
Current Ratio	5.28-2.1	7.34+3.1	4.21-4.3	8.53+4.4	4.14+1.6	2.51
Debt-to-Equity	0.30+0.1	0.21-0.2	0.42+0.2	0.18-0.3	0.46-0.4	0.84
FCF Margin	-332.0%-61.9pp	-270.1%+39.7pp	-309.7%-8.2pp	-301.5%+67.4pp	-369.0%-97.7pp	-271.3%

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	34.2%+16.6pp	17.6%-1.5pp	19.1%-5.0pp	24.1%+1.2pp	22.9%+3.8pp	19.0%-0.3pp	19.3%-9.4pp	28.7%
Operating Margin	-517.3%+215.0pp	-732.2%+17.3pp	-749.5%-268.9pp	-480.6%-13.1pp	-467.5%+7.5pp	-475.0%+15.7pp	-490.7%-160.9pp	-329.8%
Net Margin	-503.7%+236.0pp	-739.6%-9.4pp	-730.3%-259.6pp	-470.7%-34.8pp	-435.9%+18.9pp	-454.8%+10.6pp	-465.4%-158.5pp	-306.9%
Return on Equity	-19.8%+45.2pp	-65.0%-25.6pp	-39.4%-14.0pp	-25.4%-6.3pp	-19.1%-2.2pp	-16.9%+3.1pp	-20.0%-6.4pp	-13.7%
Return on Assets	-16.2%+23.3pp	-39.4%-10.6pp	-28.9%-9.3pp	-19.6%-4.0pp	-15.6%-1.4pp	-14.2%+2.5pp	-16.7%-5.4pp	-11.3%
Current Ratio	6.51+3.7	2.81-1.6	4.36-0.9	5.28-1.1	6.39-1.1	7.44-0.5	7.90+0.6	7.34
Debt-to-Equity	0.22-0.4	0.65+0.3	0.36+0.1	0.30+0.1	0.22+0.0	0.190.0	0.200.0	0.21
FCF Margin	-355.2%+145.9pp	-501.1%+97.4pp	-598.5%-236.2pp	-362.3%-24.1pp	-338.2%-60.5pp	-277.7%+70.4pp	-348.1%-98.6pp	-249.4%

Similar Companies

Icad Inc ICAD

$105.8M

Baird Medical BDMD

$66.8M

Profound Med Corp PROF

$233.7M

Avita Medical Inc RCEL

$139.1M

Sera Prognostics, Inc. SERA

$81.8M

Frequently Asked Questions

What is Inspiremd's annual revenue?

Inspiremd (NSPR) reported $7.0M in total revenue for fiscal year 2024. This represents a 13.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Inspiremd's revenue growing?

Inspiremd (NSPR) revenue grew by 13% year-over-year, from $6.2M to $7.0M in fiscal year 2024.

Is Inspiremd profitable?

No, Inspiremd (NSPR) reported a net income of -$32.0M in fiscal year 2024, with a net profit margin of -456.6%.

What is Inspiremd's EBITDA?

Inspiremd (NSPR) had EBITDA of $246.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Inspiremd's gross margin?

Inspiremd (NSPR) had a gross margin of 21.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Inspiremd's operating margin?

Inspiremd (NSPR) had an operating margin of -478.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Inspiremd's net profit margin?

Inspiremd (NSPR) had a net profit margin of -456.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Inspiremd's return on equity (ROE)?

Inspiremd (NSPR) has a return on equity of -88.7% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Inspiremd's free cash flow?

Inspiremd (NSPR) generated -$23.3M in free cash flow during fiscal year 2024. This represents a -38.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Inspiremd's operating cash flow?

Inspiremd (NSPR) generated -$21.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Inspiremd's total assets?

Inspiremd (NSPR) had $46.8M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Inspiremd's capital expenditures?

Inspiremd (NSPR) invested $1.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Inspiremd spend on research and development?

Inspiremd (NSPR) invested $13.6M in research and development during fiscal year 2024.

How many shares does Inspiremd have outstanding?

Inspiremd (NSPR) had 27M shares outstanding as of fiscal year 2024.

What is Inspiremd's current ratio?

Inspiremd (NSPR) had a current ratio of 5.28 as of fiscal year 2024, which is generally considered healthy.

What is Inspiremd's debt-to-equity ratio?

Inspiremd (NSPR) had a debt-to-equity ratio of 0.30 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Inspiremd's return on assets (ROA)?

Inspiremd (NSPR) had a return on assets of -68.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Inspiremd's cash runway?

Based on fiscal year 2024 data, Inspiremd (NSPR) had $18.9M in cash against an annual operating cash burn of $21.9M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Inspiremd's Piotroski F-Score?

Inspiremd (NSPR) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Inspiremd's earnings high quality?

Inspiremd (NSPR) has an earnings quality ratio of 0.68x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Inspiremd?

Inspiremd (NSPR) scores 42 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.